Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HLA-DRB3/4/5-based susceptibility profiles in nivolumab-induced type 1 diabetes and interstitial lung disease.

Frontiers in immunology - 1 Jan 2026

Nishikido Shinpei, Mishima Hiroyuki, Yoshiura Koh-Ichiro, Sakamoto Noriho, Ishimoto Hiroshi, Morimoto Shimpei, Horie Ichiro, Akazawa Satoru, Haraguchi Ai, Tsujiguchi Hiromasa, Hara Akinori, Tajima Atsushi, Hosomichi Kazuyoshi, Mukae Hiroshi, Kawakami Atsushi, Abiru Norio

Abstract excerpt

Immune checkpoint inhibitors (ICIs) can induce severe immune-related adverse events (irAEs), including type 1 diabetes (ICI-T1D) and interstitial lung disease (ICI-ILD); however, predictive genetic markers have not yet been fully elucidated. Accordingly, this study aimed to identify genetic polymorphisms associated with susceptibility to nivolumab-induced ICI-T1D and ICI-ILD. To address this, whole-genome...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Diabetes Mellitus, Type 1
Share to Genome-Wide Association Study

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HLA-DR4 Antigen

Share to HLA-DRB3 Chains

Share to HLA-DRB4 Chains

Share to HLA-DRB5 Chains

Share to Immune Checkpoint Inhibitors

Share to Lung Diseases, Interstitial

Source

Open in PubMed Open full text

Identifiers

PMID: 42311662
DOI: 10.3389/fimmu.2026.1840622
PMCID: PMC13269219

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HLA-DRB3/4/5-based susceptibility profiles in nivolumab-induced type 1 diabetes and interstitial lung disease.PMID 42311662Read ↗

Clinical and HLA genotype analysis of immune checkpoint inhibitor-associated diabetes mellitus: a single-center case series from China.Semantic proximity Read ↗

Human Leukocyte Antigens and Biomarkers in Type 1 Diabetes Mellitus Induced by Immune-Checkpoint Inhibitors.Semantic proximity Read ↗

HLA class II alleles and haplotypes associated with susceptibility to type 1 diabetes and to type 1 diabetes with concomitant autoimmune diseases: a cross-sectional study from Eastern Croatia.Semantic proximity Read ↗

Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitorsSemantic proximity Read ↗

Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse eventsSemantic proximity Read ↗

A multi-ancestry genome-wide association study in type 1 diabetesSemantic proximity Read ↗

Genetic discovery and risk prediction for type 1 diabetes in individuals without high-risk HLA-DR3/DR4 haplotypesSemantic proximity Read ↗

Amino acid polymorphisms in human histocompatibility leukocyte antigen class II and proinsulin epitope have impacts on type 1 diabetes mellitus induced by immune-checkpoint inhibitorsSemantic proximity Read ↗

Genetic differences between type 1 diabetes with and without other autoimmune diseases.Semantic proximity Read ↗

Genetic factors affecting immune phenotypes in type 1 diabetesSemantic proximity Read ↗

Genetic association of T1D stratified by HLA DR3 and DR4 status reveals heterogeneity in pathways of progression to T1DSemantic proximity Read ↗

A multi-ancestry genome-wide association study in type 1 diabetes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.